Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / ALXO - ALX Oncology: Trying To Justify The Hype


ALXO - ALX Oncology: Trying To Justify The Hype

2024-04-18 13:26:18 ET

Summary

  • ALX Oncology's main focus is the CD47 blocker evorpacept, which has shown encouraging results in combination with other therapies for various cancers.
  • The company has a strong financial position with enough runway to fund operations into early 2026.
  • There is both potential and risk associated with evorpacept, as it has shown positive early data but nothing convincing, so the long-term outlook is very unclear.

Top-Line Summary and Update

For further details see:

ALX Oncology: Trying To Justify The Hype
Stock Information

Company Name: ALX Oncology Holdings Inc.
Stock Symbol: ALXO
Market: NASDAQ
Website: alxoncology.com

Menu

ALXO ALXO Quote ALXO Short ALXO News ALXO Articles ALXO Message Board
Get ALXO Alerts

News, Short Squeeze, Breakout and More Instantly...